
|Videos|May 18, 2023
EMERALD Trial of Elacestrant in ER+, HER2- Advanced Breast Cancer: Efficacy and Safety Data
Expert oncologist Virginia Kaklamani, MD, DSc, joins the Oncology Brothers in highlighting the efficacy and safety data from the EMERALD trial and identifying appropriate use of elacestrant in patients with ER+, HER2- advanced breast cancer.
Advertisement
Advertisement
Advertisement
Advertisement
Trending on Targeted Oncology - Immunotherapy, Biomarkers, and Cancer Pathways
1
Indefinite Myeloma Maintenance Shows No OS Benefit vs 2-Year Duration
2
Allogeneic CD70 CAR T-Cell Therapy Shows Activity in Refractory Kidney Cancer
3
Pembrolizumab Plus Denosumab Shows Activity in Pretreated Kidney Cancer
4
Behind the FDA Approval: Isatuximab On-Body Injector Supports ‘Patient-Centric’ Priorities in Multiple Myeloma
5


























